Solventum Corporation (NYSE:SOLV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $90.27.
SOLV has been the topic of several research analyst reports. Mizuho set a $113.00 target price on shares of Solventum in a research report on Thursday, August 6th. Weiss Ratings cut shares of Solventum from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Monday, November 9th. BTIG Research reaffirmed a "buy" rating on shares of Solventum in a research note on Friday, November 6th. Canadian Imperial Bank of Commerce set a $35.00 price target on shares of Solventum in a report on Wednesday, October 28th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Solventum in a research note on Thursday, October 8th.
Read Our Latest Stock Report on Solventum
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Laurel Wealth Advisors LLC acquired a new stake in shares of Solventum during the 3rd quarter valued at approximately $29,000. JNBA Financial Advisors grew its holdings in shares of Solventum by 71.9% in the 2nd quarter. JNBA Financial Advisors now owns 507 shares of the company's stock worth $39,000 after acquiring an additional 212 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of Solventum in the 2nd quarter worth approximately $47,000. Ancora Advisors LLC acquired a new stake in shares of Solventum in the 2nd quarter worth approximately $56,000. Finally, Root Financial Partners LLC purchased a new position in Solventum in the 3rd quarter valued at approximately $68,000.
Solventum Stock Down 0.3%
SOLV opened at $88.85 on Monday. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.03 and a quick ratio of 0.72. The business has a 50 day simple moving average of $87.53 and a 200-day simple moving average of $78.95. The stock has a market capitalization of $15.08 billion, a P/E ratio of 99.83, a P/E/G ratio of 1.27 and a beta of 0.69. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16.
Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.45 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.11. The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.93 billion. Solventum had a return on equity of 25.03% and a net margin of 1.91%. Solventum's quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.50 earnings per share. On average, equities analysts anticipate that Solventum will post 7.26 earnings per share for the current fiscal year.
About Solventum
(
Get Free Report)
Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M's healthcare business and became an independent public company in April 2024. The company's offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.